VRTX vs ZYME · P/E 30, rev $12.00B vs rev $76.3M
Vertex Pharmaceuticals Inc (VRTX) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
VRTX currently screens at market cap $106.87B and trailing P/E 29.7. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the VRTX and ZYME stock pages for the full models.
Not investment advice.